Danish peptide specialist
Zealand Pharma is a Copenhagen-based peptide drug discovery company with a portfolio spanning obesity (survodutide with Boehringer Ingelheim, petrelintide), short bowel syndrome (glepaglutide), and rare diseases. Zealand's in-house peptide engineering platform has produced multiple clinical-stage assets across metabolic and rare disease indications.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| Survodutide | Obesity (BI partnership) | Phase 3 | GLP-1/Glucagon Dual |
| Petrelintide | Obesity | Phase 2 | Amylin analog |
| Glepaglutide | Short Bowel Syndrome | Phase 3 | GLP-2 analog |
| Dasiglucagon | Congenital Hyperinsulinism | FDA Approved (Zegalogue) | Glucagon analog |
How artificial intelligence is transforming gene editing, from designing better guide RNAs to predicting protein structures and engineering novel gene editors.
Eli Lilly acquired Verve Therapeutics for $1.3 billion in July 2025 — the biggest signal yet that big pharma believes in one-time genetic cures for chronic diseases.